3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Colorectal Neoplasms
114
Neoplasms
37
Neoplasm Metastasis
24
Stomach Neoplasms
22
Pancreatic Neoplasms
19
Colonic Neoplasms
15
Rectal Neoplasms
13
Esophageal Squamous Cell Carcinoma
13
Sarcoma
10
Esophageal Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Small Cell Lung Carcinoma
8
Sarcoma, Ewing
8
Breast Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Glioblastoma
7
Ovarian Neoplasms
6
Gastrointestinal Neoplasms
6
Uterine Cervical Neoplasms
5
Solid Tumors
5
Recurrence
5
Neuroblastoma
5
Intestinal Neoplasms
5
Digestive System Neoplasms
5
Cholangiocarcinoma
5
Advanced Solid Tumor
5
Rhabdomyosarcoma
4
Gastrointestinal Diseases
4
Endometrial Neoplasms
4
Digestive System Diseases
4
Interventions
adavosertib
5
durvalumab
3
Paclitaxel
3
olaparib
2
ceralasertib
2
Fluorouracil
2
Carboplatin
2
toripalimab
1
sintilimab
1
factor IX, factor VII, factor X, prothrombin drug combination
1
drug XX Z
1
danvatirsen
1
capivasertib
1
Rifampin
1
Omeprazole
1
Leucovorin
1
Itraconazole
1
Irinotecan
1
Gemcitabine
1
Cisplatin
1
AZD0156
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Solid Tumours
×
Irinotecan
×
Clear all
NCT02588105
2022-09-19
AToM
AstraZeneca
Phase 1
Completed
84 enrolled